Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Leap Therapeutics Inc LPTX

Healthcare Biotechnology
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic... see more

Recent & Breaking News (NDAQ:LPTX)

Moore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law Firm

PR Newswire February 5, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX

PR Newswire January 31, 2023

SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

PR Newswire January 30, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LPTX, DCT, AQUA, ISO

PR Newswire January 25, 2023

LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders

Business Wire January 24, 2023

SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations

PR Newswire January 23, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout

Newsfile January 19, 2023

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Leap Therapeutics, Inc. - LPTX

PR Newswire January 18, 2023

SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.

PR Newswire January 18, 2023

Leap Therapeutics Acquires Flame Biosciences

PR Newswire January 17, 2023

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

PR Newswire January 11, 2023

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

PR Newswire November 21, 2022

Leap Therapeutics Reports Third Quarter 2022 Financial Results

PR Newswire November 14, 2022

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

PR Newswire November 7, 2022

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

PR Newswire October 17, 2022

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

PR Newswire October 12, 2022

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

PR Newswire October 5, 2022

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

PR Newswire September 7, 2022

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

PR Newswire September 6, 2022

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

PR Newswire September 4, 2022